2024
Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapy
2019
Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance
Kaufhold S, Yaesoubi R, Pitzer VE. Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance. Clinical Infectious Diseases 2019, 68: s96-s104. PMID: 30845324, PMCID: PMC6405272, DOI: 10.1093/cid/ciy1108.Peer-Reviewed Original ResearchConceptsChronic carriersAntimicrobial-resistant infectionsProportion of casesTyphoid-endemic settingsTyphoid infectionVaccination coverageResistant infectionsFuture vaccination campaignsOne-way sensitivity analysesTyphoid Conjugate VaccineTransmission dynamic modelSalmonella enterica serovar TyphiEmpiric prescribingConjugate vaccineEnterica serovar TyphiIntroduction of typhoidTreatment strategiesVaccination campaignTotal casesHealth outcomesNumber of casesRate of recoveryInfectionResistant strainsTotal number